Skip to main content
. 2021 May 7;9(5):e001904. doi: 10.1136/jitc-2020-001904

Figure 2.

Figure 2

Quantification of the degree of agreement between tumor mutational burden (TMB) determination methods in non-small cell lung cancer (NSCLC) samples categorized by PD-L1 expression. (A, E) Images of NSCLC tumor samples categorized by their PD-L1 expression, as detected by immunohistochemistry with anti-PD-L1 22C3 PharmDx antibody. Tumor samples were categorized as: PD-L1<1% (A, N=55) or PD-L1≥1% (E, N=41). (B–D, F–H) Correlation plots of the TMBtotal of Oncomine Tumor Mutation Load (OTML) versus TruSight Oncology 500 (TSO500) (B, F), TSO500 versus Foundation One (FO) (C, G) and OTML versus FO (D, H) for PD-L1-negative and PD-L1-positive groups, respectively, as indicated in the graphs. (I, J) Degree of agreement shown by the concordance correlation coefficients based on three comparisons for each group of tumors. Bland-Altman plots and other parameters such as average difference, SD, 95% limits of agreement, and 95% CI of the CCCs are shown in online supplemental figures 3 and 4. Scale bar represents 100 µm.